Abstract AB0986 - 
Results: Seven patients with MEFV gene mutations were reviewed, all of them were women, ranging in age from 14 to 61 years old. Two of them had recurrent knee monoarthritis, one had a history of arthritis in the hands and erratic arthralgias, one had erratic arthralgias and two had no musculoskeletal manifestations. The 2 patients with intermittent hydrartrosis responded satisfactorily to colchicine, but not the other patients with other musculoskeletal manifestations. Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterizing recurrent self-limiting attacks of inflammation mainly placed in serosal surfaces of the body with fever (1). Colchicine is an important weapon of the humanity in FMF treatment yet. However, the puzzle of inflammation was solved, and so, inflammasome complex and interleukin-1 were discovered. Eventually, new era started with anti-interleukin-1 agents in colchicine resistant and/or intolerant FMF patients (2) . Objectives: The aim of this study is to evaluate the effectiveness of antiinterleukin-1 (anti-IL-1) agents on the characteristics of attacks, the adverse effects associated with anti-IL-1 treatment, and relation between therapy and MEFV gene mutations in 23 FMF patients with resistant and/or intolerant to colchicine. Methods: Between January 2015 and December 2016, twenty-three-FMF patients that following-up at Cumhuriyet University Medical Faculty Rheumatology-Internal Medicine Department were included in to the study. Anakinra (69,6%), and canacinumab (30,4%)] were used in 23 FMF patients. 20 cases were resistant to colchicine, 3 were intolerant to colchicine. Results: The median age of the patients was 28 years,(18-54) and the median age at diagnosis was 20 years . Of the FMF patients, nine (39.1%) were female and fourteen (60.9%) were male. The distribution of MEFV gene mutation frequencies in the FMF patients was no mutation in one (4,3.%) patient, M694V heterozygous in nine (39,1%), M694V homozygous in 7 (30,4%), E148Q heterozygous in one (4,3%), and compound heterozygous mutation in 3. (13%) patients. 16 patients used anakinra (100mg/day) for 6 mounths (median) and 7 used canacinumab (150mg/2 months) for 3 mounths (median). Four of 7 patiens were resistant to anakinra. After a median follow up 6 months overall clinical response [no attack (18 patients) or decreased frequency of attacks (5 patients)] was %100. In an FMF patient with no mutation, his brother and mother had FMF with no mutations on MEFV gene. We achieved good clinical and laboratory responses in the patient by canacinumab. Conclusions: Anti-IL-1 agents can be got involved in a new place safely and effectively in FMF patients along with colchicine. In addition, whole gene analysis should be done in refractory FMF patients with no mutations in order to could investigate new mutations, epigenetic mechanisms or other unexplained reasons. Background: Beta-thalassemia major is accompanied by progressive multiple organ systems involvement due to the disease pathophysiology as well as iron overload from blood transfusions on a regular basis. Rheumatologists are not frequently involved in the multidisciplinary management of the disease, in which rheumatologic complications are relatively common.
Conclusions
Objectives: To highlight the rheumatologic complications of beta-thalassemia, which include musculoskeletal manifestations such as arthritis and arthropathies, joint effusions, osteoporosis, bone fractures, and arthralgias as well as connective tissue diseases such as pseuoxanthoma elasticum (PXE). Methods: We searched the literature through GoogleScholar and PubMed for all publications reporting on rheumatologic manifestations in beta-thalassemia. The following keywords were used: thalassemia, rheumatoid arthritis, osteoarthritis, iron-overload, septic arthritis, deferiprone-related arthropathy, crystal arthritis, effusions, osteoporosis, fractures, bone marrow hyperplasia, scoliosis, aseptic necrosis, arthralgia, myalgia, and pseudoxanthoma elasticum. All reports published between 1970 and 2016 were included. Results: Arthralgia and low back pain are among the most common musculoskeletal manifestations of thalassemia. Many studies are reporting an increased rate of RA in hemoglobinopathies such as thalassemia, the association of which may be attributed to genetic factors. Arthritis may develop secondary to iron deposition in the synovial tissue or due to iron chelators such as deferiprone, which may provoke a self-limited arthritis due to synovial destruction sustained by free radicals production during iron interchange. Several studies reported increased incidence (16%>30%) of arthropathy in beta-thalassemia patients on deferiprone therapy. Multiple etiologies contribute to osteoarthritis in thalassemia patients such as bone marrow expansion, iron deposition within the joint, and hypoparathyroidism. Only few cases of Salmonella enteriditis septic arthritis were described in thalassemia patients. The associations between osteoporosis and hypogonadism, diabetes, and vitamin D and calcium deficiency were found significant. Skin lesions of PXE were reported in up to 16% in beta-thalassemics.
Conclusions:
The pathophysiology of thalassemia and subsequent blood transfusions affect almost every organ system. Rheumatologic manifestations ranging from musculoskeletal complications to connective tissue diseases are common among thalassemia patients. Rheumatologists are highly encouraged to be involved in the multidisciplinary approach for the management of beta-thalassemia. Background: Myelodysplastic syndromes (MDS) are characterized by ineffective and dysplastic hematopoiesis resulting in peripheral blood cytopenias with varying risk for progression to acute myelogenous leukemia (AML) 1 . Autoimmune manifestations have been well described in association with MDS 2 . Peri-arteritis has rarely been reported. Objectives: Here, we present a novel association of MDS with peri-arteritis. Methods: Three patients within our institution and one in the literature were identified. Patients were diagnosed with MDS according to 2008 World Health Organization classification with concomitant occurrence of peri-arteritis on imaging 3 . Results: See Table 1 . Conclusions: Autoimmune manifestations associated with MDS occur in 7-25% of patients. The most commonly reported conditions include vasculitis, inflammatory arthritis and connective tissue disease. There is a paucity of literature describing peri-arteritis associated with MDS 2 . Review of the literature revealed only one other case of peri-arteritis associated with MDS outside of those identified at our facility 4. With this case series, we report peri-arteritis as a novel presentation of MDS. Peri-vascular inflammation may mimic idiopathic retroperitoneal fibrosis, however, persistent cytopenias, lack of response to immunosuppressive therapy and persistence of elevated inflammatory markers should prompt the physician to evaluate for an underlying diagnosis of MDS.
Abstract AB0990 - Despite treatment, disease was complicated by aortic dissection which was managed non-operatively. Azacitidine was initiated but she died of infectious complications.
Epipharyngeal mass improved with corticosteroids. Disease course was complicated by infection.
